Drug Warning: Razadyne
Generic name: galantamine hydrobromide (class of drugs known as acetylcholinesterase inhibitors)
Manufactured and marketed by: Ortho-McNeil, a subsidiary of Johnson and Johnson
Purpose: Designed to treat patients who suffer from mild to moderate cases of Alzheimer's disease. Galantamine has recently had its name changed in 2005 from Reminyl to Razadyne, in an effort to avoid confusion with the diabetes drug Amaryl.
Side Effects Reported
- Results from two clinical studies reported that the patients taking the drug had a higher rate of death than another group taking a placebo.
Industry Report
The FDA has asked Johnson and Johnson to add a new warning to the labeling of Reminyl concerning recent findings from clinical studies. According to the FDA, they along with additional international health authorities are reviewing the safety of Reminyl. A total of 15 of the patients taking Reminyl during the study died either while taking the drug or within 30 days after discontinuation of the drug.
Seeger Weiss is not currently pursuing lawsuits on this drug, but its drug warnings will remain on our radar.
- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
